Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4646642 | 0.80 | MAPK14 (0.52) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL3374511 | 0.80 | PTPN1 (0.65) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL13982997 | 0.79 | RIPK2 (0.59) | MAPK14PTPN1RIPK2RAB9ASMN1; SMN2 | |
| SCHEMBL3375740 | 0.79 | MAPK14 (0.76) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL2792560 | 0.78 | MAPK14 (0.72) | MAPK14PTPN1RIPK2 | |
| SCHEMBL3376508 | 0.78 | MAPK14 (0.56) | MAPK14PTPN1RIPK2LMNARAB9A | |
| Hydrochloric Acid SCHEMBL28362888 | 0.78 | MAPK14 (0.74) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL1335080 | 0.76 | RIPK2 (0.78) | MAPK14PTPN1RIPK2RAB9ASMN1; SMN2 | |
| SCHEMBL3376392 | 0.74 | HTT (0.67) | MAPK14PTPN1RIPK2LMNARAB9A | |
| SCHEMBL31547878 | 0.74 | PTPN1 (0.51) | MAPK14PTPN1RIPK2LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200519-A1 | TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-08-21 | — | — | US | disclosed |
| EP-1958934-A1 | Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200519-A1 | TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | PTGES, PTGS1, PTGS2 | MAPK14 1641/4885PTPN1 4630/4885RIPK2 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.